In this issue:
Safety of ustekinumab and vedolizumab during pregnancy
Second-line anti-TNF vs. vedolizumab drug survival in IBD
Cost-effectiveness of 5-aminosalicylates + biologic/tofacitinib for UC
Colectomy rates for UC in England during 2003–2016
Location, not severity, of lesions influences endoscopic CD remission
Vedolizumab vs. adalimumab for CD
No COVID in IBD patients in Hong Kong/Taiwan
Infliximab exposure, not trough concentration, correlates with infections
Intestinal microbiome composition and symptoms in successfully treated IBD
Tofacitinib for real-world UC
Please login below to download this issue (PDF)